Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 2
1986 1
1987 2
1992 3
1993 1
1994 1
1996 2
1998 1
1999 3
2001 1
2002 1
2003 1
2004 1
2005 2
2006 2
2007 2
2008 3
2009 1
2010 2
2011 3
2012 6
2013 3
2014 5
2015 3
2016 1
2017 1
2018 4
2019 3
2020 2
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, Vij R, Sharpnack D, Chan P, de la Cruz C, Sadowsky J, Seshasayee D, Koerber JT, Pillow TH, Phillips GD, Rowntree RK, Boswell CA, Kozak KR, Polson AG, Polakis P, Yu SF, Dragovich PS, Agard NJ. Dela Cruz Chuh J, et al. Among authors: boswell ca. MAbs. 2021 Jan-Dec;13(1):1862452. doi: 10.1080/19420862.2020.1862452. MAbs. 2021. PMID: 33382956 Free PMC article.
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Lo AA, Johnston J, Li J, Mandikian D, Hristopoulos M, Clark R, Nickles D, Liang WC, Hötzel K, Dunlap D, Pham T, Cai H, Ovacik M, Bravo-Perez D, Mai E, Slaga D, Ellerman D, Ziai J, Totpal K, Lee G, Boswell CA, Payandeh J, Wu Y, Junttila TT. Lo AA, et al. Among authors: boswell ca. Mol Cancer Ther. 2021 Apr;20(4):716-725. doi: 10.1158/1535-7163.MCT-20-0490. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536191
68 results